Arrowhead Pharma CEO Sells $85 Million — All Three Filing Insiders Exit to Zero

Every insider who recently filed a Form 4 at Arrowhead Pharmaceuticals (ARWR) now holds zero shares. CEO Christopher Richard Anzalone leads the group with $85.3 million in career sales, and all three filing insiders have completely exited their positions.

CEO Sells $85.3 Million Over 170 Transactions

Anzalone has been one of the most active insider sellers in the biotech sector. Across 170 transactions, the CEO has generated $85.3 million in proceeds. His most recent wave of sales — totaling $24.3 million — brought his share count to exactly zero.

For a CEO who has led the company through its pivot to RNA interference therapeutics and a partnership with Amgen, the complete divestiture is notable. Arrowhead's pipeline centers on cardiometabolic and liver diseases, with its lead candidate plozasiran in late-stage trials.

Three-for-Three: Complete Exit

Insider	Title	Career Sales	Transactions	Shares After
Christopher Anzalone	Chief Executive Officer	$85.3M	170	0
William D. Waddill	Executive	$5.9M	74	0
Adeoye Y. Olukotun	Executive	$2.5M	67	0

The Supporting Cast

William D. Waddill sold $5.9 million across 74 transactions, with $3.4 million in recent sales clearing his position. Adeoye Y. Olukotun sold $2.5 million across 67 transactions, with $1.7 million recently, also exiting completely.

Combined, the three insiders generated $93.7 million in career sales across 311 transactions — and collectively hold zero shares of the company.

Pipeline Context

Arrowhead is a clinical-stage biotech valued at roughly $4 billion. The company's RNAi platform has attracted significant pharma partnerships, but the insider selling comes at a time when several key programs face near-term catalysts. When every actively filing insider has exited, the signal extends beyond routine diversification.

Track Arrowhead insider activity on the ARWR stock page.